Should I buy or sell DocMorris stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DocMorris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZRSEF shares. View ZRSEF analyst ratings or view top-rated stocks .

How have ZRSEF shares performed in 2024?

DocMorris' stock was trading at $75.80 at the beginning of the year. Since then, ZRSEF shares have increased by 26.3% and is now trading at $95.77. View the best growth stocks for 2024 here .

Are investors shorting DocMorris?

DocMorris saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 255,400 shares, an increase of 21.7% from the March 15th total of 209,900 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days. View DocMorris' Short Interest .

How do I buy shares of DocMorris?

Shares of ZRSEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ZRSEF

DocMorris (ZRSEF) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ZRSEF Stock Alerts

$95.77

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $95.77
▼
$95.77
50-Day Range: $88.60
▼
$108.05
52-Week Range: $33.00
▼
$108.05

Volume: N/A
Average Volume: 117 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Headlines Short Interest

Get DocMorris alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About DocMorris Stock (OTCMKTS:ZRSEF)

DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers prescription and over-the-counter medicines, consumer health products, beauty and personal care products, nutritional supplements, painkillers, and first aid products. It also provides professional health care services. The company sells its products to online mail-order pharmacies, and private individuals under the PromoFarma by DocMorris, TeleClinic, and DocMorris brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.

ZRSEF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZRSEF Stock News Headlines

April 16, 2024 | markets.businessinsider.com

DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market

April 13, 2024 | americanbankingnews.com

DocMorris AG (OTCMKTS:ZRSEF) Short Interest Up 21.7% in March

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 23, 2024 | seekingalpha.com

DocMorris AG (ZRSEF) Q4 2023 Earnings Call Transcript

March 21, 2024 | msn.com

DocMorris AG reports FY results; initiates FY24 outlook

March 6, 2024 | morningstar.com

Leafly Holdings Inc LFLY

January 16, 2024 | morningstar.com

DocMorris AG ZRE

January 16, 2024 | markets.businessinsider.com

DocMorris achieves significant revenue growth in the fourth quarter of 2023 and confirms inflection point by increasing active customer base

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

January 9, 2024 | morningstar.com

DocMorris AG DOCM

January 2, 2024 | wsj.com

DocMorris N.V.

December 17, 2023 | morningstar.com

DocMorris AG ZRSEF

December 8, 2023 | morningstar.com

Pineapple Inc PNPL

November 11, 2023 | morningstar.com

Clicks Group Ltd ADR CLCGY

August 17, 2023 | msn.com

DocMorris AG GAAP EPS of CHF12.12, revenue of CHF462.9M

May 12, 2023 | msn.com

Umbenennung: Online-Apotheke Zur Rose Group wird zu Doc Morris

May 5, 2023 | markets.businessinsider.com

Annual General Meeting 2023: Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM)

May 4, 2023 | markets.businessinsider.com

Zur Rose Group has successfully completed the sale of its Swiss business to Migros

March 23, 2023 | news.yahoo.com

Zur Rose delays profitability break-even to 2024

March 23, 2023 | marketwatch.com

Zur Rose Shares Slump After Pushing Break-Even Target to 2024

February 8, 2023 | finanznachrichten.de

Zur Rose Group: Ist das der Beginn einer Trendwende?

February 7, 2023 | msn.com

Zur Rose Group is upgraded by Deutsche Bank to a hold rating

February 7, 2023 | investing.com

Citi Upgrades Zur Rose Group AG to Neutral

February 3, 2023 | finanznachrichten.de

Zur Rose Group verabschiedet sich vom Schweizer Markt - Aktie springt nach oben

February 3, 2023 | markets.businessinsider.com

Zur Rose Group hands over successful Swiss business to Migros to focus on growth in Germany

January 19, 2023 | finanznachrichten.de

Zur Rose Group: Aktie reagiert mit Kurssprung auf Erhöhung der Ergebnisprognose

January 19, 2023 | msn.com

Online pharmacy Zur Rose improves 2022 core loss target

See More Headlines

Receive ZRSEF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DocMorris and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical Retailers
Sub-Industry: N/A
Current Symbol: OTCMKTS:ZRSEF
CUSIP: N/A
CIK: N/A
Web: www.zurrosegroup.com
Phone: (152) 724-0020
Fax: N/A
Employees: 1,453
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Walter Oberhansli (Age 66)
Founder & Chairman
Comp: $478k
Mr. Walter Hess (Age 59)
CEO & Member of Executive Board
Comp: $1.51M
Mr. Marcel Ziwica (Age 49)
CFO & Member of Executive Board
Mr. David Maso (Age 53)
Head of Europe & Member of Executive Board
Mr. Madhu Nutakki (Age 53)
CTO & Member of Executive Board
Mr. Kaspar Niklaus (Age 56)
COO & Member of Executive Board
Dr. Daniel Grigat
Group Head of Investor Relations & Sustainability

Key Competitors

View All Competitors

ZRSEF Stock Analysis - Frequently Asked Questions

Should I buy or sell DocMorris stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DocMorris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZRSEF shares.
View ZRSEF analyst ratings or view top-rated stocks.
How have ZRSEF shares performed in 2024?: DocMorris' stock was trading at $75.80 at the beginning of the year. Since then, ZRSEF shares have increased by 26.3% and is now trading at $95.77.
View the best growth stocks for 2024 here.
Are investors shorting DocMorris?: DocMorris saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 255,400 shares, an increase of 21.7% from the March 15th total of 209,900 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.
View DocMorris' Short Interest.
How do I buy shares of DocMorris?: Shares of ZRSEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ZRSEF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

DocMorris (ZRSEF) Stock Price, News & Analysis

About DocMorris Stock (OTCMKTS:ZRSEF)

ZRSEF Stock Price History

ZRSEF Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ZRSEF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info